It is noteworthy that a significant adverse drug event association with pancreatitis has been previously established by various works for the related drug class of GLP-1 receptor agonists in the setting of pharmacologic treatment of type 2 diabetes mellitus (T2DM). This evidence concerns the gene GLP1R and pancreatitis.